Loading data for BIOA — first visit, this takes a few seconds.
BioAge Labs, Inc. (BIOA)
NasdaqGS: BIOA
· Real-Time Price · USD
8.44
-0.21 (-2.43%)
At close: Sep 10, 2026, 3:59 PM
The price, the headline numbers and the latest news, in one place.
BioAge Labs, Inc. (BIOA) Stock Price, Analysis & Data
-2.43% (1D)
| Bid | 6.27 |
| Market Cap | 386M |
| Revenue (ttm) | 10.4M |
| Net Income (ttm) | -94.5M |
| 0.00 | |
| -2.39 | |
| n/a | |
| -3.48 | |
| P/B (ttm) | 1.03 |
| P/S (ttm) | 37.23 |
| Earnings Date | Nov 5, 2026 |
| Ask | 10.91 |
| Volume | 127,223 |
| Avg. Volume (20D) | 875,217 |
| Open | 8.71 |
| Previous Close | 8.65 |
| Day's Range | 8.44 - 8.88 |
| 52-Week Range | 4.68 - 25.95 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BIOA
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the tre...
Sector Healthcare
IPO Date Sep 26, 2024
Employees 60
Stock Exchange NasdaqGS
Ticker Symbol BIOA
Website https://bioagelabs.com
Financial Performance
In 2025, BioAge Labs's revenue was 9M, an increase of undefined% compared to the previous year's 0. Earnings were -80.61M, an increase of 13.35%.
Financial StatementsEarnings Surprise
BioAge Labs has released their quarterly earnings on Aug 5, 2026:
- Revenue of $2.45M misses estimates by $0, with 1.62% YoY growth.
- EPS of -0.58 exceeds estimates by 0.04, with 3.33% YoY growth.
BioAge Labs, Inc. is scheduled to release its earnings on Nov 5, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2